Table 1.
Pathway | Inhibitor name | Inhibitor concentration (uM) | Inhibition of transformationa (%) | Reversion of transformed phenotype |
---|---|---|---|---|
Janus protein tyrosine kinase | JAK inhibitor I | 0.001 | n.a.b | No |
0.005 | n.a. | No | ||
0.01 | n.a. | No | ||
0.015 | n.a. | No | ||
0.05 | n.a. | No | ||
0.15 | 0 | No | ||
VEGFR | VEGF receptor 2 kinase inhibitor III | 1 | 0 | No |
20 | n.a. | Txc | ||
SRC (family) | PP2 | 5 | 41 | No |
10 | 73.4 | No | ||
PP1 | 0.0015 | No | ||
0.015 | 0 | No | ||
Genistein | 25 | 11.9 | No | |
Inhibitor I | 0.044 | n.a. | No | |
0.088 | n.a. | No | ||
0.44 | n.a. | No | ||
0.88 | 0 | No | ||
Inhibitor II | 1.2 | 0 | No | |
12 | TX | Tx | ||
Emodin | 0.018 | n.a. | No | |
18.5 | 0 | No | ||
185 | n.a. | Tx | ||
SU 6656 | 0.28 | n.a. | No | |
1 | 22 | n.a. | ||
2.8 | 65.9** | Yes | ||
Lavendustin C | 2 | 4 | No | |
Damnacanthal | 0.017 | n.a. | No | |
0.17 | 0 | No | ||
Platelet derived growth factor receptor (PDGF) | Inhibitor I | 0.2 | n.a. | No |
2 | n.a. | No | ||
Inhibitor II | 1.1 | n.a. | No | |
11 | 57.5 | No | ||
Inhibitor III | 0.05 | n.a. | No | |
0.08 | 20 | No | ||
0.5 | n.a. | No | ||
0.8 | 0 | No | ||
AG 1296 | 1 | n.a. | No | |
10 | n.a. | No | ||
AG 2043 | 1 | n.a. | No | |
10 | 29.2 | No | ||
EGFR | PD 153035 | 0.000025 | n.a. | No |
0.00025 | 0 | No | ||
AG 1478 | 0.003 | n.a. | No | |
0.03 | 0 | No | ||
HSP 90 | Herbimycin A | 0.2 | 96 | n.a. |
0.4 | 100 | Yes | ||
Geldanamycin | 0.0017 | 0 | n.a. | |
0.0075 | 74 | n.a. | ||
0.0187 | 90 | n.a. | ||
0.0375 | 97.9 | Yes | ||
0.075 | Tx | Yes | ||
0.75 | Tx | Yes | ||
Radicicol | 0.27 | n.a. | Yes | |
2.7 | 55.7 | Yes | ||
17-DMAG | 0.5 | 88.8 | Yes |
Inhibition of transformation was calculated by comparing the number of foci obtained by the JSRV Env in the presence of each inhibitor or in the presence of DMSO alone (taken as 100%). Values shown are the average of at least two experiments.
Not analysed
A toxic effect was evident at these concentrations